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3H-Spiroperidol Binding to Peripheral Mononuclear 
Cells in Schizophrenic and Healthy Subjects 
Norbert Wodarz, Jiirgen Fritze, Peter Riederer, and Helmut Beckmann 
3H-spiroperidol binding to peripheral blood mononuclear cells was measured in 28 patients, 
who fulfilled DSM-lll-R-criteria for schizophrenia nd 17 healthy subjects. There were no 
significant differences in characteristic binding parameters (Ka, Bm~) between schizophrenic 
and healthy subjects. Moreover, there was no relation of binding parameters to any of the 
subtypes of schizophrenia orto the course of illness according to DSM-lll-R-criteria. However, 
some patients exhibited higher Bm~ values without having a unique clinical symptomatology 
according to known diagnostic riteria. Neuroleptic treatment had no consistent effect on 
binding parameters intraindividually. Ka and Bm~ values were not related to age or gender. 
In conclusion, despite our previously reported improved methodology, we were not able to 
corroborate the clinical importance of this "peripheral marker" as a tool for diagnosing 
schizophrenia or for predicting the response to neuroleptic treatment in our sample of schizo- 
phrenic patients. 
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Introduction 
In recent years research in the field of psychiatry focused 
ora the evaluation of biological markers. Peripheral blood 
mononuclear cells (PBMC) are known to possess pecific 
binding sites for several neurotransmitters, such as/3-ad- 
rPnPro l r  rPt'~.ntnr~ (Wi l l iarng et al 1076) ,  muscarinic ho- 
~ ~ , , v = ~ . v  . v~v_ l~ . . . . . . . . . . . . . . . . . . . . . . .  I . . . . . . . . . . . . . .  
linergic receptors (Strom et al 1974), receptors for sub- 
stance P (Payan et al 1983), and vasoactive intestinal peptide 
(VIP) (Danek et al 1983). 
As reported by LeFur et al (1980), murine and human 
PBMC reveal specific binding of the D2-antagonist pi- 
roperidol. These authors proposed this binding as ape- 
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ripheral model of the central D2-dopamine r ceptor site. 
Consequently, in line with the dopamine hypothesis, a
significant and selective increase in binding capacity (Bm,~,) 
for 3H-spiroperidol inlymphocytes from schizophrenic pa- 
tients was described (LeFur et al 1983; Rotstein et al 1983; 
Bondy et al 1984; Halbach and Henning 1989; Grodzicki 
et ai i990). Moreover, Bondy and Ackenheil (1987) re- 
ported a similar increase of Bma,, in healthy relatives of 
schizophrenics. This group suggested increased 3H-spi- 
roperidol binding as a genetic vulnerability marker for 
schizophrenia. 
Interestingly, a decreased binding capacity has been 
detected in patients with idiopathic Parkinson's disease 
(LeFur et al 1980; Czlonkowska et al 1987; Bondy et al 
1989). However, selection criteria of schizophrenic pa- 
tients, methodological details, and even Bm~, and Kd values 
of healthy subjects differ widely between research groups. 
Moreover, considerable ffort in various laboratories to 
reproduce these results failed (Bloxham et al 1981; Fie- 
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minger et al 1982; Maloteaux et al 1982; Shaskan et al 
1983; Feenstra et al 1989; ltzchaky et al 1989; Rao et al 
1990). In previous reports we described in detail that some 
well-known, but obviously uncontrolled pitfails in binding 
assays using viable cells might have contributed to this 
controversy. Moreover, because of an atypically shaped 
saturation curve, different mathematical methods to ana- 
lyze the data were used throughout the literature (Wodarz 
et al 1989, 1992). 
The potential clinical importance of 3H-spiroperidol 
binding to lymphocytes as a tool to diagnose schizophre- 
nia, to identify individuals at risk (Bondy and Ackenheil 
1987) and/or to predict the response to neuroleptic treat- 
ment (Grodzicki et al 1990) led us to reinvestigate 28 
patients fulfilling DSM-lll-R-criteria of schizophrenia with 
our previously reported methodology. 
Methods  
Subjects 
Venous blood was collected from 28 schizophrenic npa- 
tients (21 men, 7 women; mean age 33.1 - 12.4 [+SD] 
years) and 17 healthy individuals (14 men, 3 women; mean 
age 28.5 +_ 11.9 years) in the morning hours between 8
and 10 AM. Patients fulfilled DSM-III-R-criteria for 
schizophrenia. DSM-III-R (APA 1987) diagnoses were 
alade independently b two psychiatrists, who were blind 
to laboratory investigations. Summarized Cllnicai and de- 
mographic data of the patients are given in Table 1. 
Nine patients were free of oral drugs for at least 4 weeks 
and free of depot neuroleptics for at least 12 weeks at the 
time of laboratory testing. Three patients had never re- 
ceived neuroleptics before. The others received neurolep- 
tics (haloperidol: 10-20 mg; clozapine: 150-500 mg per 
day) and some additional benzodiazepines (diazepam: 10- 
20 rag; lorazepam: 1-3 mg per day). 
Five initially drug-free patients were reinvestigated af- 
ter clinical improvement on maintenance therapeutic doses 
of haloperidol (decanoate 100-150 mg, every 4 weeks) or 
c!ozaoine ~-mn ,,,,,. "~n noa,,~ uo~t,t. . . . .  ~.-o..,~ . . . . . .  ~ . . . .  mg ........ s o-oj . . . .  and . uf ,~. l  I J  ] • 
age-matched and gender-matched schizophrenic patients 
were studied in parallel on the same day. All subjects were 
carefully screened for nutritional status and prevalence of 
medical illness, as well as alcohol or nicotine abuse by 
medical history, physical examination and routine labo- 
ratory investigation. One woman and her matched control 
were postmenopausal, the others were tested during the 
midluteal phase of the cycle. Controls had no present or 
past evidence of a major psychiatric disorder according to 
DSM-III-R criteria nd no family history of mental illness. 
They were free of any medication. 
Informed consent was obtained from all subjects prior 
to the investigation. This study was approved by the ethical 
committee of the University of Wiirzburg and conformed 
to the declaration of Helsinki (last revision in Hong Kong, 
1990). 
Cell Preparation 
Peripheral blood mononuclear cells (PBMC) were pre- 
pared immediately after venipuncture from ethylenedi- 
amine tetraacetic acid (EDTA) blood by sodium metri- 
zoate-Ficoll density gradient centrifugation as described 
elsewhere in detail (Wodarz et al 1991). Briefly, blood 
was diluted with Hanks Balanced Salt Solution (HBSS) 
without Ca 2+ and Mg 2+ 1/1 (v/v) and layered carefully 
on sodium metrizoate-Ficoll. After centrifugation for 30 
min (300 g; 23°C) the lymphocytes were obtained from 
the interphase. Lymphocytes were washed three times in 
Hanks Balanced Salt Solution without Ca 2+ and Mg 2+ 
(1/10 (v/v); 100 g for l0 min). The final cell count was 
performed with a Coulter Counter (Model $5, Coulter 
Electronics Ltd, GB). Viability of cells always exceeded 
98%, as judged from their ability to exclude trypan blue. 
Routine staining was performed to assure a constant com- 
position of cell suspensions. 
Binding Assays 
3H-spirooeridol binding assays were performed immedi- 
ately after cell separation using viable cells as described 
previously (Wodarz et al l an-~ r,,~,o . . . .  ,. ,.. . . . .  were suspended in 
HEPES (25 mmol/L) buffered HBSS, pH 7.4 including 
1.3 mmol/L Ca 2÷ and Mg 2÷ . To determine binding pa- 
rameters, cells were incubated with 10 different concen- 
trations of 3H-spiroperidol (30 pM-3 nM) in the presence 
or absence of 1 Ixmol/L (+)-butaclamol in 96-well mi- 
crotiter plates (NUNC, Sweden). Equilibrium was achieved 
by incubation at 37°C for 60 min in a humidified atmo- 
sphere (5% Co2; 95% air). Free ligand was separated from 
bound ligand by rapid filtration through polyethyleneimine 
(PEI; 0.3%)-pretreated Whatman GF/C filters (Whatman, 
Mmuoto,,,., . .u ,  ~el l  li~L[ ,.-.,j a • ,~lt,~,, semlautomatlc - 
vester (Flow Laboratories, Inc., Rockville, MD) followed 
by an 11-sec wash with ice-cold HBSS. The radioisotope 
was measured by a standard liquid scintillation count in a 
Beckman LS 5000 TD counter at an efficiency of about 
54%. All assays were routinely performed in duplicate. 
Chemicals 
3H-spiroperidol (specific activity: 85-95 Ci/mol/L) was 
obtained from Amersham (Braunschweig, FRG). Sodium 
melrizoate-Ficoli and polyethyleneimine were obtained from 
Sigma Chemicals Inc. (St. Louis, USA). Hanks Balanced 
Salt Solution was obtained from Biochrom KG (Berlin, 
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Table 1. Binding Parameters (Bmax, KD', arithmetic mean _+ SEM), as Estimated by Three Different Modes of Calculation (see 
Methods for deta:ds) 
(a) one saturable site 
Healthy Schizophrenic 
subjects patients 
(n = 17) (n = 28) t p 
Ko [nmol/L]: 3.21 -+ 0.50 2.69 - 0.25 !.03 0.3 
Bm~, [fMol/106 cells]: 7.82 -4- ! .30 8.88 - 1.22 -0 .57  0.6 
(b) one saturable site and omitting the 
nonsaturable part 
Healthy Schizophrenic 
subjects patients t p 
Ko [nmol/L]: 0.31 +_ 0.04 0.31 +-_ 0.04 0.09 0.9 
Bm~ [tMol/IO 6 cells] 1.12 -*- 0.16 1.88 -*- 0.41 -1 .43  0.2 
(c) one saturable site and one 
nonspecific, nonsaturable part 
Healthy Schizophrenic 
subjects patients 
Ko [nmob'L]: 0.21 __+ 0.04 0.18 - 0.02 0.94 0.4 
Bm~ [fMol/106 cells] 0.55 _ 0.08 0.62 - 0.08 -0 .51  0.6 
Binding parameters Kd and Bm~ (mean -+ SEM) of 3H-spiroperidol binding to unfractionated iymphocytes: Calculation based on the assumptions: (a) one saturable 
site in the ligand concentration range up to 3 nmol/L; (b) one saturable site (the nonsaturable part in the ligand concentration range 0.03 nmol/L-3 nmol/L was omitted); 
(c) one saturable site and one nonspecific nonsaturable part within the ligand concentration range 0.03 nmol/L-3 nmol/L. There were no statistically significant differences 
between healthy and schizophrenic subjects, irrespective of the method of calculation. 
FRG), HEPES from Serva Chemicals (Heidelberg, FRG), 
(+)-butaclamol from Research Biochemicals Inc. (Way- 
land, USA) All dilutions were made with HBSS. Because 
some subsets of PBMC are known to adhere to glassware, 
only plastic material was used throughout the experiments. 
Data Analysis 
The term "displaceable binding" defines the difference be- 
tween binding in the absence and in the presence of 1 
ttmol/L ( + )-butaclamol. Kd and Bmax values were derived 
from computerized iterative nonlinear egression analysis 
(Enzfitter, Elsevier Biosoft). The Enzfitter-software offers 
the option to weigh the data statistically and exclude "out- 
liers." The same results could be obtained by excluding 
samples with a coefficient of variation within a single 
experiment exceeding 10%. 
The following equations were used to fit the binding 
curves: (a,b) single-site model: Bound = (B,~, x Free)/(Ka 
+ Free); (c) one specific and one nonspecific binding site 
model: 
Bound = (Bmax × Free)/(Ka + Free) + (F x Free) 
where F represents the slope of the nonspecific but dis- 
palceable binding. Data were analyzed using Pearson's 
product-moment correlation, t-test for independent or de- 
pendent variables where appropriate, and analysis of co- 
variance (ANCOVA). ~ significan~ level~ ~rc ,~;c-',zil~. 
Results 
The saturation experiments in healthy and schizophrenic 
subjects revealed abiphasic saturation-curve with an initial 
part at low ligand concentrations (< 1 nmol/L) and a second 
linear part with higher ligand concentrations (1-300 nmol/L), 
which is not saturable. The mathematical methods de- 
scribed above for the calculation of Bm,~ and Kd values 
were applied to this atypically shaped "saturation curve." 
The results are shown in Table 1. 
The intraindividual coefficient of variation was below 
10%. However, there was a large interindividual variation 
of Bmax and Ka values in healthy and schizophrenic sub- 
jects. The amount of interindividual nd intraindividual 
scattering depended on the mode of calculation (Table 1). 
The same statistical results were obtained, irrespective 
of the mathematical model applied to analyze the "satu- 
ration curve." We could previously demonstrate hat the 
complex model of one specific and one nonspecific binding 
site is the most adequate to describe this atypically shaped 
"saturation curve" (Wodarz et al 1992). Therefore, data 
are presented only for this model. There were no statis- 
tically significant differences in Bm~,, and Kd values be- 
tween the schizophrenic and healthy subjects. Moreover, 
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Figure 1. Binding affinity (Ka, Figure la) and binding capacity 
(Bm~, Figure lb) of 3H-spiroperidol to PBMC of 17 healthy 
subjects ( - )  and 28 schizophrenic patients (x). Patients were 
subclassified to type of schizophrenia according to DSM-III-R- 
criteria (295.1x; 295.2x; 295.3x). The fifth digit code "x" de- 
scribes that the course of the disease was ignored. There were 
no statistically significant differences inthe characteristic binding 
parameters between the different subtypes of schizophrenic dis- 
order or to the controls. Binding parameters Ka and B,~x were 
calculated by using the model of one s~cific an_d one nonspecific 






fmol/1 mio. cells 
~, X _ 
295.xl 295.x2 295.x3 295.x4 Contr. 
Fi~m'c 2. Binding affinity (Kd, Figure 2a) and binding capacity 
(Bm~, Figure 2b) of 3H-spiroperidol to PBMC of 17 healthy 
subjects ( - )  and 28 schizophrenic patients (x). Patients were 
subelassified to course of schizophrenic disorder according to 
DSM-III-R-criteria (295x!; 295x2; 295x3; 295x4). The fourth- 
digit code "x" describes that the subtype of the schizophrenic 
disorder was ignored. There were no statistically significant dif- 
ferences in the characteristic binding parameters between the 
different courses of the disease or to the controls. Binding pa- 
ra_meters Kd and Bmax were ,-~l,-,,l~tod according to the m~-~de! of 
one specific and one nonspecific binding site (Le Fur et al 1983; 
Bidart et al 1983; Wodarz et al 1992). 
there was no relation of characteristic binding parameters 
to any of the subtypes of schizophrenia or to the course 
of illness according to DSM-III-R-criteria (Figures 1 and 
2). 
Drug-free patients exhibited no significant differences 
in binding parameters compared to healthy subjects or 
pharmacologically treated patients. Moreover, there were 
no significant changes in intraindividual Bm~, Kd and F- 
values in five initially drug-free patients, who were rein- 
vestigated after clinical improvement on maintenance ther- 
apeutic doses of haloperidol or clozapine (Figure 3). 
Nevertheless, there were some patients, whose binding 
parameters where apparently different from those of the 
other subjects (Figures 1 and 2). Those patients exhibited 
higher Bmax values with all mathematical models applied 
to analyze the "saturation curve." However, we were un- 
able to establish a unique clinical symptomatology or course 
of the disorder according to DSM-llI-R-criteria. In addi- 
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Figure 3. Binding affinity (Kd, Figure 3a) and binding capacity 
(Bma~, Figure 3b) of 3H-spiroperidol to PBMC of 5 drug-free 
schizophrenic patients, who were reinvestigated after treatment 
with haloperidol (x) or clozapine (o). Mean ____. SD of control 
subjects is given as a reference. 
tion, there was no significant influence of age or gender 
on the binding parameters using Pearson's product-mo- 
ment correlation and ANCOVA. 
Discussion 
Initially, LeFur et al (1980b, 1983) reported an increase 
in 3H-spiroperidol binding sites on peripheral lymphocytes 
in schizophrenic patients and a decrease of these binding 
sites in idiopathic Parkinson's disease. Although some 
groups could confirm these findings in schizophrenics 
(Rotstein et al 1983; Bondy et al 1984; Halbach and Hen- 
ning 1989; Grodzicki et al 1990) and patients with Par- 
kinson's disease (Czlonkowska et al 1987; Bondy et al 
1989), others were not able to replicate a binding site for 
3H-spiroperidol in PBMC at all (Bloxham et al 1981; Fle- 
minger et al 1982; Maloteaux et al 1982; Shaskan et al 
1983; Feenstra et al 1989; Itzchaky et al 1989; Rao et al 
1990). We previously described in detail some fundamen- 
tal methodological issues, which might have contributed 
to this discrepancy OVodarz et al 1992). 
In previous studies paranoid schizophrenics (LeFur et 
al 1983; Rotstein et al 1983) were reported to exhibit the 
highest Bmax values. In contrast, our schizophrenic patients 
with a paranoid subtype according to DSM-IlI-R-criteria 
did not show significantly different binding parameters 
compared to healthy individuals. Moreover, if the patients 
were subclassified to type or course of schizophrenic dis- 
order according to DSM-lll-R-criteria, there were no sta- 
tistically significant differences in any of the characteristic 
binding parameters (Bma~, Ka) between the subgroups or 
compared to healthy subjects. However, there were three 
patients out of 28, whose Bmax values were more than one 
SD above the arithmetic mean. These three patients did 
not exhibit a unique clinical symptomatology or course of 
the disease according to DSM-III-R criteria. These patients 
might well belong to a subgroup of schizophrenic patients, 
whose disease might have a unique etiology and need a 
unique type of treatment. This might be supported by the 
actually preliminary observation that those patients did not 
respond well to neuroleptic treatment. However, some other 
patients were nonresponders to standard neuroleptics as 
well without having elevated Bm~ values. This is in cor~- 
trast to a previous study (Grodzicki et al 1990), which 
observed a striking difference in binding parameters be- 
tween neuroleptic responsive and nonresponsive patients. 
Moreover, LeFur et al (1983) described a decrease in 
binding capacity Bma~ of drug-free patients after short-time 
neuroleptic treatment and an increase after long-time 
administration of neuroleptics. However, we could not 
observe this phenomenon i our five drug-free patients, 
who were on neuroleptic treatment at the time of reinves- 
tigation. It did not matter whether the typical neuroleptic 
haloperidol or the atypical one clozapine was used. 
As we previously have described in detail (Wodarz et 
al 1992), some well-known but obviously uncontrolled 
methodological issues might have contributed to this con- 
Ixoversial results (e.g., unspecific filter binding, which 
increases in the presence of ( + )-butaclamol as a displacer, 
or a variable amount of contaminating granulocytes, which 
do not exhibit the spiroperidol binding site). Moreover, 
selection criteria of schizophrenic patients differed be- 
tween the groups. LeFur et al (1983) classified their pa- 
tients in type I syndrome (acute schizophrenics with 
positive symptoms) and type II syndrome (chronic schizo- 
phrenics with negative symptoms). Bondy et al (1984) and 
Halbach and Henning (1989) classified their patients ac- 
cording to International Classification of Diseases (ICD) 
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9 criteria, but mentioned that only a minority of patients 
fulfilled DSM-III-R criteria of schizophrenia, s the ma- 
jority of their patients uffered from their first and acute 
episode of illness. Rao et al (1990) described ICD-9 di- 
agnoses, too. Rotstein et al (1983) used the Research Di- 
agnostic Criteria. Only Itzchaky et al (1989) and Grodzicki 
et al (19,00) classified their patients according to DSM-III- 
R criteria. Most of the patients in our study were chron- 
ically ill (duration of illness > l year). 
In conclusion, we were not able to corroborate the clin- 
ical importance of this "peripheral marker" as a tool for 
diagnosing schizophrenia or for a prediction of response 
to neuroleptic treatment in our sample of schizophrenic 
patients. Apart from not exactly knowing the pharmaco- 
logical and molecular nature of the "3H-spiroperidol bind- 
ing site" in peripheral blood mononuclear cells, its phys- 
iological significance remains to be evaluated. 
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